New drug combo tested for tough-to-treat liver cancers
NCT ID NCT03092895
Summary
This study tested whether combining an immunotherapy drug (SHR-1210) with either a targeted therapy (apatinib) or standard chemotherapy could help people with advanced liver or bile duct cancer. It involved 157 participants whose cancer had spread and was not suitable for surgery. The main goal was to check if these combinations were safe and tolerable, while also measuring how well they controlled the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
81 Hospital Nanjing
Nanjing, Jiangsu, 210002, China
-
Cancer Hospital of Henan province
Zhengzhou, Henan, 450008, China
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Hunan Cancer Hospital
Hunan, Changsha, 410000, China
-
The First Affiliated Hospital of Nanchang University
Jiangxi, Nanchang, 330006, China
-
The Second Affiliated Hospital Of Anhui Medical University
Hefei, Anhui, 230000, China
-
Zhongshan Hospital
Shanghai, Shanghai Municipality, 200003, China
Conditions
Explore the condition pages connected to this study.